Clinical Trials /

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

NCT04099641

Description:

This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda. There is no expanded access program available for the investigational agents per this protocol.

Related Conditions:
  • Adenocarcinoma of the Gastroesophageal Junction
  • Gastric Adenocarcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
  • Official Title: A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy

Clinical Trial IDs

  • ORG STUDY ID: ONCG100
  • SECONDARY ID: 2019-000949-13
  • NCT ID: NCT04099641

Conditions

  • Gastric Cancer
  • GastroEsophageal Cancer

Interventions

DrugSynonymsArms
Bavituximabbavituximab and pembrolizumab
Pembrolizumab InjectionKeytrudabavituximab and pembrolizumab

Purpose

This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda. There is no expanded access program available for the investigational agents per this protocol.

Trial Arms

NameTypeDescriptionInterventions
bavituximab and pembrolizumabExperimentalBavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks
  • Bavituximab
  • Pembrolizumab Injection

Eligibility Criteria

        Inclusion Criteria:

          -  Signed written informed consent

          -  Men and women ≥ 18 years old; ≥ 20 years old in South Korea and Taiwan

          -  Unresectable metastatic or locally advanced gastric or GEJ adenocarcinoma

          -  Progressed on and/or after at least 1 prior regimen for metastatic disease

          -  Willing and able to provide fresh formalin-fixed paraffin-embedded tissue tumor sample

          -  Presence of at least one measurable lesion

          -  ECOG of 0 or 1

          -  Has adequate organ functions

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 72 hours prior to start of study treatment.

          -  Women must not be breastfeeding.

          -  Women of childbearing potential , must agree to follow instructions for highly
             effective method(s) of contraception

          -  Males who are sexually active with women of childbearing potential must agree to
             follow instructions for highly effective method(s) of contraception

          -  Has adequate treatment washout period before start of study treatment

        Exclusion Criteria:

          -  Received any form of anti-phosphatidylserine therapies

          -  Prior treatment with any checkpoint inhibitor or other therapies targeting T-cell
             control

          -  Medical history of myocardial infarction within 6 months before registration,
             symptomatic congestive heart failure (CHF) , troponin levels consistent with
             myocardial infarction, unstable angina, or serious cardiac arrhythmia

          -  Weight loss >10% over 2 months prior to first dose of study treatment

          -  History of pneumonitis that required steroids or has current pneumonitis

          -  Has known active CNS metastases/and or carcinomatous meningitis

          -  Known additional malignancy that is progressing or has required active treatment in
             within the past 3 years

          -  An active infection requiring systemic therapy

          -  Known human immunodeficiency virus (HIV) infection or known acute hepatitis B or C
             infection

          -  Unresolved toxicities from previous cancer treatments

          -  History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the study, interfere with the participant's
             participation for the full duration of the study, or is not in the best interest of
             the participant to participate, in the opinion of the treating investigator

          -  Active autoimmune disease or history of chronic recurrent autoimmune disease

          -  Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.

          -  History of infusion reactions to any component/excipient of bavituximab

          -  History of severe hypersensitivity reactions to mAbs.

          -  Systemic steroid therapy within 7 days prior to the first dose of study treatment

          -  Has received a live vaccine within 30 days prior to first dose of study drug.

          -  Prior organ transplantation including allogeneic or autologous stem-cell
             transplantation

          -  Currently participating in or has participated in a study of an investigational agent
             or has used an investigational device within 4 weeks prior to the first dose of study
             treatment

          -  Receipt of treatment with immunotherapy, biological therapies, or therapeutic doses of
             hormonal therapies within 3 weeks of scheduled C1D1 dosing

          -  Known psychiatric, substance abuse disorder, or geographical travel limitations that
             would interfere with participant's ability to cooperate with the requirements of the
             study

          -  Pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Incidence and severity of Treatment Emergent Adverse Events(TEAE)
Time Frame:From first dose through 30 days after last dose
Safety Issue:
Description:Incidence by severity of TEAEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, including changes in clinical laboratory parameters

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Oncologie Inc.

Last Updated